View Clinical Trial (Medical Research Study)

Combination Therapy in Amyotrophic Lateral Sclerosis (ALS) - NCT00919555-85018(Clinical Trial 297734)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Phoenix
State:  
AZ
Zip Code: 85018
Conditions: Amyotrophic Lateral Sclerosis
Purpose: The purpose of the study is to determine the safety and the efficacy of Tretinoin and Pioglitazone HCL in patients with ALS who are currently on Riluzole.
Study summary: Physicians at Phoenix Neurological Associates (PNA) are looking for individuals diagnosed with ALS to participate in a double-blind, placebo controlled study of Tretinoin and Pioglitazone HCL, used in combination with Riluzole, for treating ALS. This investigator initiated trial conducted by Dr. Todd Levine and Dr. David Saperstein will help determine whether Tretinoin and Pioglitazone HCL, in combination, can slow the progression of ALS. At present, there is little to no effective therapy for ALS, nor is there a known cause. Therefore there is a tremendous unmet need for more effective therapy for this disease and that is why the physicians at PNA have been very interested in the role of developing a more active anti-excitotoxic cocktail for patients with ALS. Since recent data have suggested that inflammatory mechanisms may interact with and promote neurodegeneration (where cells in the spinal cord and brain are lost), there have been a number of anti-inflammatory treatment strategies that have been evaluated in animal models. Some studies have shown that mice that were given Pioglitazone HCL demonstrated improved muscle strength and body weight, exhibited a delayed disease onset as well as had a longer survival rate compared to non treated mice. In addition to these studies, retinoic acids have been studied extensively in various models of the injured nervous system. These studies have shown that retinoic acids, such as Tretinoin may be neuroprotective and support axonal growth, which could in turn slow disease progression. The purpose of this study is to determine if such a drug "cocktail" could offer the best chance of attaining a significant reduction in disease progression by utilizing currently available FDA-approved agents
Criteria: Inclusion Criteria: - El Escorial Classification of laboratory supported probable, probable, or definite ALS - Age 18 - 85 years - Male or female - FVC greater than or equal to 70% predicted Exclusion Criteria: - Patients with FVC below 1.5 L or below 70% predicted - History of liver disease - Severe renal failure (CrCl<30) - History of coronary artery disease requiring placement of stents, bypass surgery or previous myocardial infarction - EKG at baseline with evidence for previous myocardial infarction, cardiomyopathy, or arrhythmia - History of intolerance to Riluzole, Tretinoin, or Pioglitazone HCL - History of diabetes - Any other comorbid condition which would make completion of trial unlikely
Study is available at: Phoenix Neurological Associates, LTD
Phoenix, AZ 85018
United States

Primary Contact:
Nicole C Hank, MHSM
Email: nhank@pnal.net
Phone: 602-258-2432

Secondary Contact:
Nicole C Hank, MHSM
Email: nhank@pnal.net
Phone: 602 258-2432
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.